Under construction – not a live service
Sign in
Not yet taking people in ChinaNo phase

Removing part of a lung lobe versus the whole lobe in early lung cancer

Compares two kinds of lung surgery in adults with small, early non-small cell lung cancer.

Key facts

Who runs it
Shanghai Chest Hospital
Where
Shanghai, ChinaSee the site
Trial code
Registry title
Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC
Status
Not yet recruiting
People taking part
1,200 people, planned
Started
21 Aug 2026
Expected to end
Jul 2034
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Anatomic Segmentectomy
  • Anatomic Lobectomy
Record updated
26 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a small, solid lung nodule deep in the lung that is suspected early-stage non-small cell lung cancer. It compares removing part of a lobe with removing the whole lobe.

Age
18 to 80 years
Sex
All sexes can join.
Disease stage
Clinical stage IA non-small cell lung cancer (cT1a-bN0M0). One nodule of 2 cm (0.8 in) or less, mostly solid (consolidation-to-tumor ratio above 0.5), deep in the inner two-thirds of the lung. No spread to lymph nodes or other organs.
Earlier treatment
No earlier surgery on the same side of the lung. No other cancer within 5 years.

Main reasons for not taking part

  • Lesion in the right middle lobe
  • Two or more lesions needing anatomic resection
  • Earlier surgery on the same side of the lung, or another cancer within 5 years
  • Severe heart or brain blood vessel disease or other illness that makes lobectomy unsafe
  • Planned basal segmentectomy (S7-10)

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age 18 to 80 years
  • Solitary pulmonary nodule with whole-tumor maximal diameter <=2 cm confirmed by preoperative thin-slice CT (<=1 mm) and 3D reconstruction
  • Solid-dominant nodule with consolidation-to-tumor ratio (CTR) >0.5, including pure-solid nodules
  • Deeply located lesion, defined as the lesion center located in the inner two-thirds of the lung field on axial, coronal, and sagittal MPR images
  • Clinically definite suspected primary NSCLC after complete preoperative work-up and MDT discussion, with estimated malignancy probability >=95%. Preoperative pathologic confirmation is not mandatory, but preoperative or intraoperative pathology should be obtained when technically safe and feasible
  • Complete staging with thin-slice contrast-enhanced chest CT, whole-body PET-CT, brain contrast-enhanced MRI or CT, and serum tumor markers as appropriate; clinical stage IA (cT1a-bN0M0) without regional nodal or distant metastasis
  • Cardiopulmonary function sufficient to tolerate both lobectomy and segmentectomy, with FEV1 and DLCO >=60% predicted
  • Written informed consent, including special disclosure that final pathology may be benign
  • Centralized imaging review confirmation by the lead-center technical committee before randomization

Who cannot take part

  • Lesion located in the inner two-thirds but adjacent to the lung apex or base and judged suitable for wedge resection
  • Two or more lesions requiring anatomic resection. One secondary lesion requiring only non-anatomic wedge resection is allowed; two main lesions in the same segment are excluded
  • Prior ipsilateral lung surgery or another malignancy within 5 years
  • Severe cardiovascular or cerebrovascular disease or other comorbidity making lobectomy or conversion to lobectomy intolerable
  • Lesion located in the right middle lobe
  • Planned basal segmentectomy (S7-10); proper segmentectomy is permitted

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in China

  • Shanghai Chest HospitalShanghai, ChinaContact: Qing Shanghai Chest HospitalNo longer taking part

About the trial

What the trial wants to find out

SOLID is a multicenter, open-label, randomized, controlled, phase III non-inferiority trial comparing anatomic segmentectomy with lobectomy in patients with deeply located, solid-dominant, clinical stage IA non-small cell lung cancer (NSCLC) measuring <=2 cm. Eligible participants will undergo centralized imaging review and will be randomized preoperatively in a 1:1 ratio before induction of anesthesia.

Read full original descriptionShow less

The primary endpoint is 5-year overall survival. The key supportive secondary endpoint is 5-year recurrence-free survival. The study will enroll 1,200 participants and will use intention-to-treat analysis for the primary endpoint. An independent Data and Safety Monitoring Board and an independent Endpoint Adjudication Committee will oversee safety, surgical quality, data quality, and endpoint adjudication.

The 2 groups in the trial

  • SegmentectomyTreatment being tested

    Participants assigned to this arm will undergo anatomic pulmonary segmentectomy. Combined segmentectomy or proper segmentectomy is permitted; basal segmentectomy (S7-10) is prohibited. Segmentectomy must include anatomic treatment of the segmental hilar artery, vein, and bronchus, margin assessment, and required lymph-node dissection. Conversion to lobectomy is permitted or required according to protocol-defined clinical and safety criteria.

    Treatment: Anatomic Segmentectomy

  • LobectomyExisting treatment, for comparison

    Participants assigned to this arm will undergo standard anatomic pulmonary lobectomy with required systematic or lobe-specific lymph-node dissection.

    Treatment: Anatomic Lobectomy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Comparison of Segmentectomy and Lobectomy for Deeply Located, Solid-Dominant Early-Stage Non-Small Cell Lung Cancer (<=2 cm): A Multicenter, Open-Label, Randomized, Controlled, Non-Inferiority Clinical Trial
Plain-language title
Removing part of a lung lobe versus the whole lobe in early lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07698990, who can take part
Record updated
26 August 2026